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ABSTRACT 
Psoriatic arthritis (PsA) is a relapsing inflammatory disease, most commonly a seronegative oligoarthritis found in patients with psoriasis, 
characterized by the absence of rheumatoid factor in serum, with differentiating features of distal joint involvement and in extreme cases of 
arthritis mutilans (which is a destructive form of PsA). Cardiovascular autonomic and peripheral sympathetic neuropathy occurs in PsA. However, 
there is no specific treatment recommendation for autonomic neuropathy (AN) in psoriatic diseases. Secukinumab, a recently approved therapeutic 
advancement for psoriasis and psoriatic arthritis, is an immunoglobulin G (IgG) 1k fully monoclonal antibody that selectively inhibits the effector 
function of interleukin (IL)-17A. Its effect on sudomotor dysfunction in PsA has not yet been reported. This is the first reported observation of 
improvement in peripheral sympathetic autonomic neuropathy with secukinumab in PsA. We report a case of a 52-year-old male with PsA on 
methotrexate 15 mg/week with severe disease activity treated with the addition of subcutaneous secukinumab 150 mg once a week for 5 w 
followed by once a month dose. We found significant improvement in sudomotor dysfunction after 4 and 8 w of treatment. 
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A skin and joint disease with multifactorial etiology, psoriasis affects 
1-2% of the general population [1]. Typically PsA involves joints of 
the axial skeleton with an asymmetrical pattern. The spectrum of 
symptoms includes inflammatory changes in attachments of 
articular capsules, tendons, and ligaments to the bone surface [1]. 
The disease can have a diverse clinical course but usually, manifests 
as oligoarthritis [1]. Peripheral sympathetic autonomic dysfunction 
in psoriatic arthritis is known [2]. Secukinumab is an IgG1k fully 
monoclonal antibody selectively targeting interleukin-17A. IL-17A 
neutralized by secukinumab rapidly inhibits downstream 
inflammatory cytokine and chemokine networks and thus may be 
useful for the treatments of several immune-mediated diseases [3]. 
Interleukin 17A and its receptor are expressed in synovial tissues 
and as such the interleukin 17 pathway is proposed to contribute to 
the pathogenesis of psoriatic arthritis [4]. Interleukin 17A can 
mediate a variety of effector biological functions that can result in 
joint and enthesial inflammation, damage, and tissue remodeling [4]. 
Secukinumab with an alternative form of action to current 
treatments is useful as a biologic DMARD in PsA [4]. However, its 
effect on sudomotor dysfunction in PsA has not yet been reported. 
We here report the impact of treatment with this novel drug on 
sudomotor function in a case of PsA. 
CASE REPORT 
A 52-year-old gentleman with a 25 y history of PsA being treated 
with oral methotrexate 15 mg/week since 15 y reported with 
increased joint pains and swelling for the last 9 mo. In addition to 
PsA, the patient had light-headedness and disturbed bowel 
movements suggestive of autonomic dysfunction. He is a teetotaler 
and a non-smoker. He is normotensive and non-diabetic and does 
not have thyroid dysfunction. He had an elevated erythrocyte 
sedimentation rate (ESR) of 73 mm/1st hr and high C-reactive 
protein (CRP) of 25 mg/dl and DAS-28 (Disease Activity Score in 28 
joints) score was 6.3 (table 1). Radiographs are depicted in fig. 1. 
Symptoms of ANS were measured by asking a number of questions 
according to an easily administered instrument, known as a survey 
of autonomic symptoms [5].  
 
Fig. 1A: Radiograph of sacroiliac joints, subchondral sclerotic 
changes are seen in bilateral sacroiliac joints with preserved 
joint space (Grade II Sacroilitis), fig. 1B. radiographs of hand 
joints. Reduced bone density changes are seen in bilateral 
hands. Extensive Erosive Arthritis with loss of Joint space with 
Subchondral Bone Destruction and Sclerotic changes are seen in 
right 3rd PIP and DIP joints. Ankylosis changes are seen at right 
2nd metacarpophalangeal, PIP and DIP joints. Similar ankylosis 
changes also seen at left 4th PIP Joint. Joint Space narrowing with 
subchondral sclerosis is seen at right 1st interphalangeal joint, 
4th PIP joint with osteophytes formation. Similar changes also 
were seen at left 2nd, 3rd and 4th PIP and DIP joints. Erosive 
arthritic changes also were seen at B/l trapeziometacarpal and 
2nd carpometacarpal joints with subchondral sclerotic changes 
joint space narrowing with sclerotic changes is seen at right 
Intercarpal joints, radioscaphoid joint and distal radioulnar joint 
 
The peripheral sympathetic autonomic function was measured by 
non-invasive device Sudoscan (Sudoscan Impeto Medical Device, 
EZS 01750010193 Paris, France) [6]. Sudoscan is a FDA approved 
device designed to perform the precise evaluation of sweat gland 
function based on sweat chloride concentrations through reverse 
iontophoresis and chronoamperometry. Through reverse 
iontophoresis, the device generates a voltage to the cathode and a 
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current (intensity of around 0.2 mA) between the anode and cathode 
proportional to chloride concentration. At low voltages (60 μS = no 
dysfunction; 60–40 μS = moderate dysfunction [6]. Sudomotor 
function test was performed before the initiation of treatment and 
after each treatment interval. Sudomotor function test showed 
marked abnormalities of peripheral sympathetic function (table 1 
and fig. 2). No other cause of neuropathy was found from the 
detailed clinical history, physical examination and biochemical 
screening (serum vitamin B12 deficiency, Thyroid Function Tests 
(T3, T4, TSH), fasting blood sugar, HbA1c, HbsAg, Anti-HCV, HIV). 
 
Table 1: Results of sudomotor function and clinical tests 
   Time Interval 
Variables 0 w 4 w 8 w Normal value 
Sudoscan (µs) 43 56 72 >60  
ESR (mm/1h) 73 25 10  0-10  
CRP (mg/l)  25 6 5.10 <6  
DAS-28 6.3 4.73 2.42 <2.5 
HAQ-DI 2 1 0.1 -- 
ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS-28; disease activity score of 28 joints, HAQ-DI; health assessment questionnaire. 
 
Secukinumab 150 mg subcutaneous was added to MTX 15 mg/week 
on day 0, 7, 14, 21 and day 28 as a loading dose followed by 
maintenance dose of 150 mg once a month. After the first dose of 
Secukinumab 150 mg subcutaneous, there was a rapid improvement 
in autonomic symptoms and sudomotor dysfunction (fig. 2) and 
normal values were achieved after 8 w of treatment. ESR, CRP and 
DAS-28 scores were reduced (table 1) and autonomic symptoms 
disappeared after 8 w of secukinumab administration. After 4 and 8 
w treatment with secukinumab, there was a great improvement in 
the quality of life assessed by HAQ-DI (table 1). 
  
 
Fig. 2: Sudomotor function at baseline and after 4 and 8 w of treatment with secukinumab 
 
DISCUSSION 
We have shown in this case with active psoriatic arthritis a 
significant improvement in inflammatory disease activity and 
sudomotor dysfunction along with resolution of autonomic 
symptoms after treatment with secukinumab. Syngle et al. in 2013 
first described the involvement of autonomic dysfunction in PsA 
patients with 37.5 % having moderate sudomotor dysfunction [2]. 
Haliguret al. have reported sympathetic nervous system dysfunction 
in psoriasis but did not investigate sudomotor dysfunction [7]. 
The pathogenesis of peripheral sympathetic autonomic dysfunction 
and its treatment in PsA is still unknown. Sudomotor dysfunction 
reflects small fiber neuropathy, cardiovascular autonomic neuropathy 
and peripheral sympathetic autonomic neuropathy [6]. The early 
diagnosis and appropriate treatment of autonomic neuropathy are 
important because of higher risk of CV morbidity and mortality [8]. 
Cardiovascular autonomic neuropathy is a significant risk predictor 
for sudden cardiac death in autoimmune rheumatic diseases [9]. 
In the present case study, the index patient with active PsA had 
sympathetic dysfunction along with some autonomic symptoms. 
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Secukinumab, when added to methotrexate significantly, reduced the 
high disease activity, inflammation, autonomic symptoms and abnormal 
sudomotor dysfunction. Though symptoms of autonomic dysfunction 
may be absent or occur with varying frequency and intensity, 
sympathetic nervous system dysfunction can be detected non-invasively 
and is important to prevent severe consequences including myocardial 
infarction, arrhythmias and sudden cardiac death.  
The role of proinflammatory cytokines, including TNF-α, IL-1, IL-6, IL-
8, IL-10, IL-12, IL-17 and IL-23, has been demonstrated within the 
joint in psoriatic arthritis and relationship between cytokine levels 
and clinical arthritis severity demonstrated [10]. The proinflammatory 
cytokine Interleukin 17 (IL-17) has recently emerged as a key 
proinflammatory cytokine that orchestrates immune responses during 
infection, acute inflammation, allergy and autoimmune disease. It is 
secreted by immune cells such as Th17 cells, and its receptors are 
ubiquitously expressed. Th-17 cells and innate IL-17 producers have 
been shown to be important players of IL-17-induced effects in the 
joint [11]. IL-17, being a proinflammatory cytokine, in turn, acts on 
synovium, macrophages, dendritic cells, endothelial cells, chemokines, 
entheseal cells and osteoclasts [11]. 
IL-17 effects in PsA are mediated through IL-1, IL-6, IL-8, TNF-α, 
MMP-3, receptor activator of NFκB [12]. Blockage of IL-17 receptor 
(IL-17RA) with anti-IL-17 RA antibody (secukinumab) inhibited the 
production of IL-6, IL-8 and matrix metalloproteinase-3 (MMP-3) 
[13]. Overproduction of IL-17 can affect different parts of the body 
in PsA resulting in significant disability and poor quality of life [13]. 
Through the induction of other cytokines like IL-6, TNF-α and nitric 
oxide, IL-17 may also result in complications like accelerated 
atherosclerosis and autonomic dysfunction [12]. 
Both in ankylosing spondylitis and PsA, the cytokine-mediated 
inflammatory process may contribute to the autonomic 
abnormalities [2, 14]. On the other hand, there is also evidence for 
the contribution of the nervous system to inflammation (2, 14, 15]. 
Thus it is possible that the sudomotor dysfunction associated with 
PsA is likely to be immune-mediated and driven by the inflammatory 
state that characterizes the disease. 
Hence treatment with IL-17A monoclonal antibody, secukinumab, 
through its IL-17R blocking action with resultant immune-
modulatory and anti-inflammatory effect can have beneficial effects 
on the sudomotor dysfunction of PsA. 
CONCLUSION 
To the best of our knowledge, this is the first case study to report the 
therapeutic impact of secukinumab on sudomotor dysfunction in 
active PsA. Although we were unable to investigate the mechanism 
of improvement of sympathetic dysfunction, our findings indicate 
that IL-17A blockade with secukinumab does have the immune-
modulatory and anti-inflammatory potential as well as appears to 
exert a beneficial effect on sudomotor dysfunction in PsA. This case 
report assumes significance given the fact that autonomic 
dysfunction has been linked to a reduced quality of life and serious 
and potentially life-threatening cardiovascular complications. 
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